相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Jian Xu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment
David Tenero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Can phenotypic data complement our understanding of antimycobacterial effects for drug combinations?
Frank Kloprogge et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
A model-informed preclinical approach for prediction of clinical pharmacodynamic interactions of anti-TB drug combinations
Oskar Clewe et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
Simon D. Harding et al.
NUCLEIC ACIDS RESEARCH (2018)
Assessment and modelling of antibacterial combination regimens
G. G. Rao et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
Martin J. Boeree et al.
LANCET INFECTIOUS DISEASES (2017)
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
Si-Yang Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Preclinical Efficacy Testing of New Drug Candidates
Eric L. Nuermberger
MICROBIOLOGY SPECTRUM (2017)
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
Neesha Rockwood et al.
CLINICAL INFECTIOUS DISEASES (2017)
The implications of model-informed drug discovery and development for tuberculosis
Morris Muliaditan et al.
DRUG DISCOVERY TODAY (2017)
Multidrug evolutionary strategies to reverse antibiotic resistance
Michael Baym et al.
SCIENCE (2016)
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529
Ishani Landry et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Patrick P. J. Phillips et al.
BMC MEDICINE (2016)
Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
Andreas H. Diacon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool
Klaus Romero et al.
CLINICAL INFECTIOUS DISEASES (2015)
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Anne Lenaerts et al.
IMMUNOLOGICAL REVIEWS (2015)
Immunoevasion and immunosuppression of the macrophage by Mycobacterium tuberculosis
Zakaria Hmama et al.
IMMUNOLOGICAL REVIEWS (2015)
Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis
Tawanda Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis
Emmanuel Chigutsa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Analysis of drug combinations: current methodological landscape
Julie Foucquier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Stephen H. Gillespie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Amina Jindani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis
George L. Drusano et al.
PLOS ONE (2014)
Implementation of pharmacokinetic and pharrnacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research
Tove Tuntland et al.
FRONTIERS IN PHARMACOLOGY (2014)
Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model
Jurriaan E. M. de Steenwinkel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents
Daniel Gonzalez et al.
CLINICAL MICROBIOLOGY REVIEWS (2013)
From in vitro EC50 to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: A framework
Jing Fang et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
From in vitro EC50 to in vivo dose-response for antiretrovirals using an HIV disease model. Part II: Application to drug development
Jing Fang et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
Andreas H. Diacon et al.
LANCET (2012)
Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide
Robert S. Wallis et al.
PLOS ONE (2012)
Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis
Scott G. Franzblau et al.
TUBERCULOSIS (2012)
Comparative Studies Evaluating Mouse Models Used for Efficacy Testing of Experimental Drugs against Mycobacterium tuberculosis
Mary A. De Groote et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Functional Capacity of Mycobacterium tuberculosis-Specific T Cell Responses in Humans Is Associated with Mycobacterial Load
Cheryl L. Day et al.
JOURNAL OF IMMUNOLOGY (2011)
Phase II failures: 2008-2010
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2011)
Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis
Deepak Almeida et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis
Eric Nuermberger et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis
EL Nuermberger et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
An in vivo pharmacokinetic/pharmacodynamic model for antiretroviral combination
M Legrand et al.
HIV CLINICAL TRIALS (2003)
Clinically significant interactions with drugs used in the treatment of tuberculosis
WW Yew
DRUG SAFETY (2002)
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials
WJ Burman et al.
CLINICAL PHARMACOKINETICS (2001)
分享论文
